[go: up one dir, main page]

FI971998L - Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä - Google Patents

Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä Download PDF

Info

Publication number
FI971998L
FI971998L FI971998A FI971998A FI971998L FI 971998 L FI971998 L FI 971998L FI 971998 A FI971998 A FI 971998A FI 971998 A FI971998 A FI 971998A FI 971998 L FI971998 L FI 971998L
Authority
FI
Finland
Prior art keywords
protein
free culture
biological products
producing biological
producing
Prior art date
Application number
FI971998A
Other languages
English (en)
Swedish (sv)
Other versions
FI971998A0 (fi
FI121117B (fi
Inventor
Otfried Kistner
Noel Barrett
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/487,046 external-priority patent/US5753489A/en
Priority claimed from US08/483,522 external-priority patent/US5756341A/en
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI971998A0 publication Critical patent/FI971998A0/fi
Publication of FI971998L publication Critical patent/FI971998L/fi
Application granted granted Critical
Publication of FI121117B publication Critical patent/FI121117B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI971998A 1994-11-10 1997-05-09 Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä FI121117B (fi)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US33876194A 1994-11-10 1994-11-10
US33876194 1994-11-10
US48722295A 1995-06-07 1995-06-07
US08/487,046 US5753489A (en) 1994-11-10 1995-06-07 Method for producing viruses and vaccines in serum-free culture
US48722295 1995-06-07
US48352295 1995-06-07
US08/483,522 US5756341A (en) 1994-11-10 1995-06-07 Method for controlling the infectivity of viruses
US48704695 1995-06-07
PCT/EP1995/004439 WO1996015231A2 (en) 1994-11-10 1995-11-10 Method for producing biologicals in protein-free culture
EP9504439 1995-11-10

Publications (3)

Publication Number Publication Date
FI971998A0 FI971998A0 (fi) 1997-05-09
FI971998L true FI971998L (fi) 1997-05-09
FI121117B FI121117B (fi) 2010-07-15

Family

ID=27502591

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971998A FI121117B (fi) 1994-11-10 1997-05-09 Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä

Country Status (9)

Country Link
EP (3) EP0791055B1 (fi)
JP (1) JP3158157B2 (fi)
AT (2) ATE429246T1 (fi)
CA (2) CA2415990C (fi)
DE (1) DE69535940D1 (fi)
DK (2) DK0791055T3 (fi)
ES (2) ES2378409T3 (fi)
FI (1) FI121117B (fi)
WO (1) WO1996015231A2 (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19655440B4 (de) * 1996-04-01 2013-09-05 Novartis Vaccines And Diagnostics Gmbh Verfahren zur Herstellung eines Influenzaimpfstoffs
EP2221361A3 (en) * 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
WO1998017785A1 (en) * 1996-10-18 1998-04-30 The Research Foundation For Microbial Diseases Of Osaka University Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
ES2267280T3 (es) * 1999-08-05 2007-03-01 Baxter Aktiengesellschaft Clon celular recombinante estable, su preparacion y utilizacion del mismo.
EP1211309A4 (en) * 1999-08-20 2003-02-12 METHOD AND APPARATUS FOR PROLIFERATION OF HEPATITIS VIRUS
JP4698112B2 (ja) * 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
EP2287288B1 (en) * 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
WO2005103235A1 (ja) 2004-04-19 2005-11-03 Denka Seiken Co., Ltd. ウイルスの生産方法
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2006206051B2 (en) * 2005-01-14 2012-12-13 The Royal Children's Hospital Virus recovery medium, use thereof and viral diagnostic kit including same
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
EP1982727A1 (en) * 2007-04-17 2008-10-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for purification of viral proteins
KR101190605B1 (ko) 2007-06-15 2012-10-15 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
RU2377295C1 (ru) * 2008-06-11 2009-12-27 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Питательная среда для культивирования клеток млекопитающих
US9051544B2 (en) 2008-12-30 2015-06-09 Baxter International Inc. Method of enhancing cell growth using alkyl-amine-n-oxide (AANOx)
WO2010079081A1 (en) * 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
EA201500910A1 (ru) 2009-02-10 2016-04-29 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
US20120058145A1 (en) * 2009-05-08 2012-03-08 Bruno Rene Andre Method for producing virus from cell culture involving homogenization
BR112012002151B1 (pt) 2009-07-31 2021-07-06 Baxalta GmbH método para expressar uma desintegrina e metaloproteinase com proteína de motivo trombospondina (adamts)
CN103025350A (zh) * 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
AU2015258263B2 (en) * 2010-05-21 2017-12-07 Seqirus UK Limited Influenza virus reassortment method
EP3392271B8 (en) 2010-07-08 2021-06-16 Takeda Pharmaceutical Company Limited Method of producing recombinant adamts13 in cell culture
CN104159608A (zh) 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
SG11201406407TA (en) 2012-06-29 2014-11-27 Emd Millipore Corp Methods for inactivating viruses during a protein purification process
SG11201501505WA (en) 2012-08-31 2015-03-30 Univ Alberta Methods for producing cells having a phenotype of a primary human hepatocytes and compositions
US10527551B2 (en) 2013-12-30 2020-01-07 Baxalta Incorporated Method of predicting a performance characteristic of a plant or yeast hydrolysate and its use
EP2966093A1 (en) 2014-07-07 2016-01-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
KR102477492B1 (ko) * 2016-07-15 2022-12-13 잇판사이단호진한다이비세이부쯔뵤우겐큐우카이 리소턴트 인플루엔자 바이러스 작출 방법
KR20200040750A (ko) * 2017-08-28 2020-04-20 잇판사이단호진한다이비세이부쯔뵤우겐큐우카이 리소턴트 인플루엔자 바이러스의 단계적 작출 방법
WO2020004425A1 (ja) * 2018-06-27 2020-01-02 一般財団法人阪大微生物病研究会 インフルエンザウイルスの培養方法
BR112021009083A2 (pt) 2018-11-15 2021-08-10 Aleph Farms Ltd. carne cultivada de alta qualidade, composições e métodos para produção da mesma
RU2738404C1 (ru) * 2019-08-26 2020-12-11 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ инактивации культурального ротавируса человека

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
GB8300467D0 (en) * 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
JPH04228066A (ja) * 1990-10-23 1992-08-18 Rikagaku Kenkyusho 外来遺伝子発現用培養細胞
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen

Also Published As

Publication number Publication date
EP0791055A1 (en) 1997-08-27
JP3158157B2 (ja) 2001-04-23
FI971998A0 (fi) 1997-05-09
HK1002285A1 (en) 1998-08-14
DE69535940D1 (de) 2009-06-04
WO1996015231A2 (en) 1996-05-23
EP0791055B1 (en) 2012-01-25
CA2205015A1 (en) 1996-05-23
EP2290053A1 (en) 2011-03-02
DK0791055T3 (da) 2012-04-16
EP1213030A1 (en) 2002-06-12
CA2415990C (en) 2009-07-07
EP1213030B1 (en) 2009-04-22
JPH10503093A (ja) 1998-03-24
ES2378409T3 (es) 2012-04-12
ATE429246T1 (de) 2009-05-15
ES2323490T3 (es) 2009-07-17
WO1996015231A3 (en) 1996-08-01
FI121117B (fi) 2010-07-15
CA2415990A1 (en) 1996-05-23
DK1213030T3 (da) 2009-07-20
ATE542891T1 (de) 2012-02-15
CA2205015C (en) 2003-04-08

Similar Documents

Publication Publication Date Title
FI971998L (fi) Menetelmä biologisten tuotteiden tuottamiseksi proteiinittomassa viljelmässä
FI951794L (fi) Menetelmä tärkkelyspitoisten tuotteiden valmistamiseksi
IL117423A0 (en) Phosphonomonoester nucleic acids process for their preparation and their use
FI971530A7 (fi) Lipaasi, sitä tuottava mikro-organismi, menetelmä lipaasin valmistamis eksi ja sen käyttö
FI955594A7 (fi) Menetelmä ja laite jäähdytettyjen ilmastettujen tuotteiden valmistamiseksi
FI950822A7 (fi) Koristelumenetelmä ja -tuote
DE69610121D1 (de) Methode zur präparation von mischprodukten
ATE258180T1 (de) Verfahren zur herstellung von glufosinate und zwischenprodukte dafür
FI971857L (fi) Menetelmä ei-diabetogeenisen maidon tai maitotuotteiden selektoimiseksi ja näin selektoitu maito tai maitotuote
FI946021A7 (fi) Levymuodossa oleva kivituote, menetelmä ja sopiva väline sen valmistam iseksi
FI960193A7 (fi) Menetelmä mikro-organismien deaktivoimiseksi
FI973351A7 (fi) Menetelmä kovien vaahtojen valmistamiseksi ja niistä valmistetut tuott eet
ATE260043T1 (de) Verfahren zur herstellung von aseptischer konsummilch
FI911882A7 (fi) Menetelmä vierasproteiinien valmistamiseksi streptomykeeteissä
FI955076A7 (fi) Elintarviketuote ja menetelmä sen valmistamiseksi
EP0795027A4 (en) IN VITRO SYNTHESIS OF PROTEINS
DE69604213D1 (de) Mikrowellenfeste Lebensmittelverpackung sowie Verfahren zur Herstellen derselben
FI971781A7 (fi) Menetelmä raaka-aineen hyödyntämisen parantamiseksi käymisprosesseissa
FI944507A7 (fi) Menetelmä oksotuotteiden valmistamiseksi
FI964121A7 (fi) Menetelmä amidokarboksyylihappojen valmistamiseksi vedessä
FI951442A7 (fi) Menetelmä entsyymien ja mikro-organismien deaktivoimiseksi
EP0818958A4 (en) METHODS OF REDUCING STEROLS IN EGGS
HUP9801884A3 (en) Methods for maintaining sterility in plants
FI964002A7 (fi) Menetelmä 7-hydroksitaksaanien valmistamiseksi
EP0506666A4 (en) Method for the production of catalytic rna in bacteria

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 121117

Country of ref document: FI

MM Patent lapsed